GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
Feladilimab Phase II Combination Study With Keytruda Halted
Executive Summary
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
You may also be interested in...
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Six Questions For GSK Ahead Of Crucial Investor Day
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Walmsley Under Pressure Over GSK’s Strategy
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.